Statins, the most widely used drugs in the Western world, have become a pivotal component in the primary and secondary prevention of vascular diseases. Although benefits have been well documented in younger-than-75-year-old individuals, the value of statins in people aged > 75 years and over is controversial. The CTT meta-analysis calculated an absolute risk reduction of 0.6%/year per 38.7 mg/dl reduction in LDL-C levels in patients aged > 75 years, that would translate into a number needed to treat of 167. However, the absolute effect of a 38.7 mg/dl cholesterol lowering on the rate of annual ischemic heart disease mortality is 10-fold larger in older vs younger patients. In order to advise physician prescription, three major Guidelines have been published over the last few years, i.e. the AHA/ACC and the NLA in the US, and the ESC/EAS in Europe. Moreover, statin prescription in the elderly should also consider the cardiovascular outcomes of elderly patients reported in classical statin preventive trials which give important clues on adherence and persistence of use, as well as on drug safety. The present review discusses benefits of intensive vs moderate statin therapy, justifications for the use of aggressive lipid management in the very old and the use of statins in frail elderlies. The final decision on the therapeutic strategy with statins in elderlies at higher risk to develop cardiovascular events should be always based on a careful analysis of the patient's general health and on the presence of metabolic abnormalities or drug interactions potentially leading to risk.

Appropriateness of statin prescription in the elderly / M. Ruscica, C. Macchi, C. Pavanello, A. Corsini, A. Sahebkar, C.R. Sirtori. - In: EUROPEAN JOURNAL OF INTERNAL MEDICINE. - ISSN 0953-6205. - (2018). [Epub ahead of print] [10.1016/j.ejim.2017.12.011]

Appropriateness of statin prescription in the elderly

M. Ruscica;C. Macchi;C. Pavanello;A. Corsini;Sirtori, C. R.
2018

Abstract

Statins, the most widely used drugs in the Western world, have become a pivotal component in the primary and secondary prevention of vascular diseases. Although benefits have been well documented in younger-than-75-year-old individuals, the value of statins in people aged > 75 years and over is controversial. The CTT meta-analysis calculated an absolute risk reduction of 0.6%/year per 38.7 mg/dl reduction in LDL-C levels in patients aged > 75 years, that would translate into a number needed to treat of 167. However, the absolute effect of a 38.7 mg/dl cholesterol lowering on the rate of annual ischemic heart disease mortality is 10-fold larger in older vs younger patients. In order to advise physician prescription, three major Guidelines have been published over the last few years, i.e. the AHA/ACC and the NLA in the US, and the ESC/EAS in Europe. Moreover, statin prescription in the elderly should also consider the cardiovascular outcomes of elderly patients reported in classical statin preventive trials which give important clues on adherence and persistence of use, as well as on drug safety. The present review discusses benefits of intensive vs moderate statin therapy, justifications for the use of aggressive lipid management in the very old and the use of statins in frail elderlies. The final decision on the therapeutic strategy with statins in elderlies at higher risk to develop cardiovascular events should be always based on a careful analysis of the patient's general health and on the presence of metabolic abnormalities or drug interactions potentially leading to risk.
Settore MED/04 - Patologia Generale
Settore BIO/14 - Farmacologia
5-gen-2018
EUROPEAN JOURNAL OF INTERNAL MEDICINE
Article (author)
File in questo prodotto:
File Dimensione Formato  
EJINME_3750_201801001397131402.pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 540.52 kB
Formato Adobe PDF
540.52 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/543098
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 33
social impact